Support Your Metabolism with Clinically-Studied Ingredients

Mitolyn — 6 plant-based nutrients to boost mitochondrial health, energy & natural fat burning.

★★★★★ 127,000+ customers · 90-day money-back guarantee

Dr. Johnny Adkins, MD

General Practice Fayetteville, AR Male

NPI: 1164472908

Total Payments

$190,536

2024 Payments

$27,408

Companies

Transactions

134

Payment Breakdown by Category

Consulting$189,878 (99.7%)

Food & Beverage$658.02 (0.3%)

Payments by Nature

Nature of Payment	Amount	Transactions	Share
Consulting Fee	$189,878	90	99.7%
Food and Beverage	$658.02	44	0.3%

Top Paying Companies

Company	Total	Records	Latest Year
Takeda Pharmaceuticals U.S.A., Inc.	$120,254	56	$0 (2024)
Shire North American Group Inc	$69,624	34	$0 (2019)
Novo Nordisk Inc	$138.72	10	$0 (2019)
Astellas Pharma US Inc	$80.27	6	$0 (2019)
Allergan Inc.	$73.49	4	$0 (2017)
SANOFI-AVENTIS U.S. LLC	$65.41	5	$0 (2018)
GlaxoSmithKline, LLC.	$60.36	4	$0 (2017)
Amgen Inc.	$50.51	2	$0 (2018)
Valeant Pharmaceuticals North America LLC	$45.42	2	$0 (2017)
PFIZER INC.	$44.90	4	$0 (2019)

Payment History by Year

Year	Amount	Transactions	Top Company
2024	$27,408	12	Takeda Pharmaceuticals U.S.A., Inc. ($27,408)
2023	$17,822	8	Takeda Pharmaceuticals U.S.A., Inc. ($17,822)
2022	$25,608	12	Takeda Pharmaceuticals U.S.A., Inc. ($25,608)
2021	$25,008	12	Takeda Pharmaceuticals U.S.A., Inc. ($25,008)
2020	$24,408	12	Takeda Pharmaceuticals U.S.A., Inc. ($24,408)
2019	$23,901	19	Shire North American Group Inc ($23,808)
2018	$23,392	23	Shire North American Group Inc ($23,208)
2017	$22,989	36	Shire North American Group Inc ($22,608)

All Payment Transactions

134 individual payment records from CMS Open Payments — Page 1 of 6

Date	Company	Product	Nature	Form	Amount	Type
12/09/2024	Takeda Pharmaceuticals U.S.A., Inc.	—	Consulting Fee	Cash or cash equivalent	$2,284.00	General
11/13/2024	Takeda Pharmaceuticals U.S.A., Inc.	—	Consulting Fee	Cash or cash equivalent	$2,284.00	General
10/09/2024	Takeda Pharmaceuticals U.S.A., Inc.	—	Consulting Fee	Cash or cash equivalent	$2,284.00	General
09/11/2024	Takeda Pharmaceuticals U.S.A., Inc.	—	Consulting Fee	Cash or cash equivalent	$2,284.00	General
08/09/2024	Takeda Pharmaceuticals U.S.A., Inc.	—	Consulting Fee	Cash or cash equivalent	$2,284.00	General
07/12/2024	Takeda Pharmaceuticals U.S.A., Inc.	—	Consulting Fee	Cash or cash equivalent	$2,284.00	General
06/10/2024	Takeda Pharmaceuticals U.S.A., Inc.	—	Consulting Fee	Cash or cash equivalent	$2,284.00	General
05/10/2024	Takeda Pharmaceuticals U.S.A., Inc.	—	Consulting Fee	Cash or cash equivalent	$2,284.00	General
04/17/2024	Takeda Pharmaceuticals U.S.A., Inc.	—	Consulting Fee	Cash or cash equivalent	$2,284.00	General
03/11/2024	Takeda Pharmaceuticals U.S.A., Inc.	—	Consulting Fee	Cash or cash equivalent	$2,284.00	General
02/14/2024	Takeda Pharmaceuticals U.S.A., Inc.	—	Consulting Fee	Cash or cash equivalent	$2,284.00	General
01/17/2024	Takeda Pharmaceuticals U.S.A., Inc.	—	Consulting Fee	Cash or cash equivalent	$2,284.00	General
12/15/2023	Takeda Pharmaceuticals U.S.A., Inc.	—	Consulting Fee	Cash or cash equivalent	$2,284.00	General
11/10/2023	Takeda Pharmaceuticals U.S.A., Inc.	—	Consulting Fee	Cash or cash equivalent	$2,284.00	General
10/09/2023	Takeda Pharmaceuticals U.S.A., Inc.	—	Consulting Fee	Cash or cash equivalent	$2,284.00	General
09/13/2023	Takeda Pharmaceuticals U.S.A., Inc.	—	Consulting Fee	Cash or cash equivalent	$2,284.00	General
07/14/2023	Takeda Pharmaceuticals U.S.A., Inc.	—	Consulting Fee	Cash or cash equivalent	$2,284.00	General
06/14/2023	Takeda Pharmaceuticals U.S.A., Inc.	—	Consulting Fee	Cash or cash equivalent	$2,134.00	General
04/07/2023	Takeda Pharmaceuticals U.S.A., Inc.	—	Consulting Fee	Cash or cash equivalent	$2,134.00	General
02/08/2023	Takeda Pharmaceuticals U.S.A., Inc.	—	Consulting Fee	Cash or cash equivalent	$2,134.00	General
12/07/2022	Takeda Pharmaceuticals U.S.A., Inc.	—	Consulting Fee	Cash or cash equivalent	$2,134.00	General
11/09/2022	Takeda Pharmaceuticals U.S.A., Inc.	—	Consulting Fee	Cash or cash equivalent	$2,134.00	General
10/05/2022	Takeda Pharmaceuticals U.S.A., Inc.	—	Consulting Fee	Cash or cash equivalent	$2,134.00	General
09/09/2022	Takeda Pharmaceuticals U.S.A., Inc.	—	Consulting Fee	Cash or cash equivalent	$2,134.00	General
08/17/2022	Takeda Pharmaceuticals U.S.A., Inc.	—	Consulting Fee	Cash or cash equivalent	$2,134.00	General

1 2 3…6 »

About Dr. Johnny Adkins, MD

Dr. Johnny Adkins, MD is a General Practice healthcare provider based in Fayetteville, Arkansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1164472908.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Johnny Adkins, MD has received a total of $190,536 in payments from pharmaceutical and medical device companies, with $27,408 received in 2024. These payments were reported across 134 transactions from 17 companies. The most common payment nature is "Consulting Fee" ($189,878).

16,000 Woodworking Plans

Step-by-step blueprints for any project. Beginner to expert.

Detailed schematics Cutting lists & materials Lifetime access — $67

★★★★★ 60-day guarantee

Get Instant Access

Practice Information

Specialty General Practice
Location Fayetteville, AR
Active Since 05/11/2006
Last Updated 03/25/2008
Taxonomy Code 208D00000X
Entity Type Individual
NPI Number 1164472908

Products in Payments

BYSTOLIC (Drug) $61.45
MYRBETRIQ (Drug) $58.27
Tresiba (Drug) $55.51
Prolia (Biological) $50.51
Victoza (Drug) $49.97
ANORO (Drug) $49.51
TOUJEO (Drug) $35.39
SOLIQUA (Drug) $30.02
RELISTOR ORAL (Drug) $26.67
CHANTIX (Drug) $22.70
LYRICA (Drug) $22.20
Levemir (Drug) $21.67
XIFAXANIBSD (Drug) $18.75
INVOKANA (Drug) $18.08
FARXIGA (Drug) $14.89
SPIRIVA RESPIMAT (Drug) $13.92
HYSINGLA ER (Drug) $13.75
TRULICITY (Drug) $13.60
Tymlos (Biological) $13.60
VRAYLAR (Drug) $12.04

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.